Levels of asymmetric dimethylarginine (ADMA),an endogenous nitric oxide synthase inhibitor,and risk of coronary artery disease: A meta-analysis based on 4713 participants
Restricted accessResearch articleFirst published online March, 2016
Levels of asymmetric dimethylarginine (ADMA),an endogenous nitric oxide synthase inhibitor,and risk of coronary artery disease: A meta-analysis based on 4713 participants
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial nitric oxide synthase by competing with L-arginine. As a result, the expression of nitric oxide decreases and endothelial dysfunction occurs. Studies have evaluated the association between the serum ADMA level and risk of coronary artery disease. However, conflicting results have been obtained.
Methods
Pubmed, Web of Science, Embase, Ovid, Cochrane databases were searched to identify eligible studies published in English until December 2014. Association was assessed on the basis of weighted mean differences (WMD) with 95% confidence intervals (CIs). Publication bias was analysed using Begg’s and Egger’s tests. Sensitivity analysis was performed to evaluate result stability.
Results
A total of 16 case–control studies with 2939 patients and 1774 controls were included in the meta-analysis. Pooled result indicated that patients with coronary artery disease yielded a higher ADMA level than healthy controls (WMD: 0.248, 95% CI: 0.156–0.340; p = 1.16 e–7). Sensitivity analysis suggested that our meta-analysis result was stable. Subgroup analysis found a similar pattern in patients with myocardial infarction (WMD: 0.397, 95% CI: 0.112–0.683; p = 0.0106), stable angina pectoris (WMD: 0.197, 95% CI: 0.031–0.364; p = 0.02) and unstable angina pectoris (WMD: 0.857, 95% CI: 0.293–1.420; p = 0.003).
Conclusions
Meta-analysis results indicated that an increased ADMA level is associated with an increased risk of coronary artery disease.
KakimotoYAkazawaS. Isolation and identification of N-G,N-G- and N-G,N'-G-dimethyl-arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J Biol Chem1970; 245: 5751–5758.
2.
UenoSSanoAKotaniK. Distribution of free methylarginines in rat tissues and in the bovine brain. J Neurochem1992; 59: 2012–2016.
MacAllisterRJFicklingSAWhitleyGS. Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol1994; 112: 43–48.
5.
LandmesserUHornigBDrexlerH. Endothelial function: A critical determinant in atherosclerosis. Circulation2004; 109: II27–II33.
6.
PalmerRMReesDDAshtonDS. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun1988; 153: 1251–1256.
7.
VallancePLeoneACalverA. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet1992; 339: 572–575.
8.
FardATuckCHDonisJA. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol2000; 20: 2039–2044.
9.
MiyazakiHMatsuokaHCookeJP. Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis. Circulation1999; 99: 1141–1146.
10.
MatsuokaHItohSKimotoM. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension1997; 29: 242–247.
11.
HoldenDPFicklingSAWhitleyGS. Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am J Obstet Gynecol1998; 178: 551–556.
12.
YooJHLeeSC. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis2001; 158: 425–430.
13.
HerlitzHPeterssonASigstromL. The arginine-nitric oxide pathway in thrombotic microangiopathy. Scand J Urol Nephrol1997; 31: 477–479.
14.
XuanCChangFJLiuXC. Endothelial nitric oxide synthase enhancer for protection of endothelial function from asymmetric dimethylarginine-induced injury in human internal thoracic artery. J Thorac Cardiovasc Surg2012; 144: 697–703.
15.
LuTMDingYACharngMJ. Asymmetrical dimethylarginine: A novel risk factor for coronary artery disease. Clin Cardiol2003; 26: 458–464.
16.
Kayacelebi AA, Willers J, Pham VV, et al. Plasma homoarginine, arginine, asymmetric dimethylarginine and total homocysteine interrelationships in rheumatoid arthritis, coronary artery disease and peripheral artery occlusion disease. Amino Acids 2015. Epub ahead of print 25 January 2015. DOI: 10.1007/s00726-015-1915-3.
17.
XuanCZhangBBLiM. No association between APOE epsilon 4 allele and multiple sclerosis susceptibility: A meta-analysis from 5472 cases and 4727 controls. J Neurol Sci2011; 308: 110–116.
18.
XuanCZhangBBYangT. Association between OCTN1/2 gene polymorphisms (1672C-T, 207G-C) and susceptibility of Crohn’s disease: A meta-analysis. Int J Colorectal Dis2012; 27: 11–19.
19.
TianQWXuanCWangHW. Diagnostic accuracy of glycosylated hemoglobin in Chinese patients with gestational diabetes mellitus: A meta-analysis based on 2,812 patients and 5,918 controls. Genet Test Mol Biomarkers2013; 17: 687–695.
20.
XuanCLunLMZhaoJX. PTPN22 gene polymorphism (C1858T) is associated with susceptibility to type 1 diabetes: A meta-analysis of 19,495 cases and 25,341 controls. Ann Hum Genet2013; 77: 191–203.
21.
XuanCBaiXYGaoG. Association between polymorphism of methylenetetrahydrofolate reductase (MTHFR) C677T and risk of myocardial infarction: A meta-analysis for 8,140 cases and 10,522 controls. Arch Med Res2011; 42: 677–685.
22.
XuanCLiHZhaoJX. Association between MTHFR polymorphisms and congenital heart disease: A meta-analysis based on 9,329 cases and 15,076 controls. Sci Rep2014; 4: 7311–7311.
23.
SchulzeFLenzenHHanefeldC. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: Results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J2006; 152: 493 e1–8.
24.
MeinitzerASeelhorstUWellnitzB. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem2007; 53: 273–283.
25.
KremplTKMaasRSydowK. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J2005; 26: 1846–1851.
26.
BaeSWStuhlingerMCYooHS. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol2005; 95: 729–733.
27.
SelcukMTSelcukHTemizhanA. Asymmetric dimethylarginine plasma concentrations and L-arginine/asymmetric dimethylarginine ratio in patients with slow coronary flow. Coron Artery Dis2007; 18: 545–551.
28.
MaasRSchulzeFBaumertJ. Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: Prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem2007; 53: 693–701.
29.
IribarrenCHussonGSydowK. Asymmetric dimethyl-arginine and coronary artery calcification in young adults entering middle age: The CARDIA Study. Eur J Cardiovasc Prev Rehabil2007; 14: 222–229.
30.
MurrCMeinitzerAGrammerT. Association between asymmetric dimethylarginine and neopterin in patients with and without angiographic coronary artery disease. Scand J Immunol2009; 70: 63–67.
31.
GadMZHassaneinSIAbdel-MaksoudSM. Assessment of serum levels of asymmetric dimethylarginine, symmetric dimethylarginine and L-arginine in coronary artery disease. Biomarkers2010; 15: 746–752.
32.
AktozTAktozMTatliE. Assessment of the relationship between asymmetric dimethylarginine and severity of erectile dysfunction and coronary artery disease. Int Urol Nephrol2010; 42: 873–879.
33.
CaoYYangKZhangZ. Correlation between plasma asymmetric dimethylarginine and different types of coronary heart disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban2010; 35: 301–306.
34.
BekpinarSGurdolFUnlucerciY. Serum levels of arginase I are associated with left ventricular function after myocardial infarction. Clin Biochem2011; 44: 1090–1093.
35.
DjordjevicBVPavlovicRCosicV. High clinical accuracy of asymmetric dimethylarginine and symmetric dimethylarginine in patients with ischemic heart disease. Amino Acids2012; 43: 2293–2300.
36.
YucelHOzaydinMDoganA. Plasma concentrations of asymmetric dimethylarginine, nitric oxide and homocysteine in patients with slow coronary flow. Scand J Clin Lab Invest2012; 72: 495–500.
37.
KruszelnickaOSurdackiAGolayA. Differential associations of angiographic extent and severity of coronary artery disease with asymmetric dimethylarginine but not insulin resistance in non-diabetic men with stable angina: A cross-sectional study. Cardiovasc Diabetol2013; 12: 145–145.
38.
Gurel E, Tigen K, Karaahmet T, et al. Predictive value of plasma asymmetric dimethylarginine, homocysteine, and high-sensitive CRP levels in occult coronary artery disease: A multidetector-row computed tomography study. Herz 2013. Epub ahead of print 21 December 2013. DOI: 10.1007/s00059-013-4022-9.
39.
JawalekarSLKarnikABhuteyA. Risk of cardiovascular diseases in diabetes mellitus and serum concentration of asymmetrical dimethylarginine. Biochem Res Int2013; 2013: 189430–189430.
40.
ShivkarRRAbhangSA. Ratio of serum asymmetric dimethyl arginine (ADMA)/nitric oxide in coronary artery disease patients. J Clin Diagn Res2014; 8: CC04–CC06.
41.
YongPJKohCHShimWS. Endothelial microparticles: Missing link in endothelial dysfunction. Eur J Prev Cardiol2013; 20: 496–512.
42.
TauilKMGaioEMelo-SilvaCA. Pulmonary arterial hypertension and sepsis: Prothrombotic profile and inflammation can changes pulmonary mechanics. Med Hypotheses2014; 83: 290–291.
43.
BogerRHRonES. L-arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev2005; 10: 14–23.
44.
IgnarroLJBushPABugaGM. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun1990; 170: 843–850.
45.
AchanVBroadheadMMalakiM. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol2003; 23: 1455–1459.
46.
OgawaTKimotoMSasaokaK. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem1989; 264: 10205–10209.
47.
PouSKeatonLSurichamornW. Mechanism of superoxide generation by neuronal nitric-oxide synthase. J Biol Chem1999; 274: 9573–9580.
